Company
NextPoint Therapeutics
| Industry | clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway |
|---|
Funding raised
| Company | Round | Date |
|---|---|---|
| NextPoint Therapeutics | Series B Extension | 2024-02-15 |